NSD1
NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.
Overview
Histone methyltransferase that dimethylates Lys-36 of histone H3 (H3K36me2). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.68, somatic mutation 0.74, genetic literature 0.83). IntOGen calls it a driver in 15 cohorts (3 activating, 12 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Adenocarcinoma, Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Melanoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.
- 1 · What it is
NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
Histone methyltransferase that dimethylates Lys-36 of histone H3 (H3K36me2). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context.
- 3 · How drugs use it
No product in this corpus aims at NSD1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:14234 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96L73 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000165671 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: head and neck squamous cell carcinoma 0.54, acute myeloid leukaemia 0.66, myeloproliferative neoplasm 0.66, leukaemia 0.67 (GraphQL API, CC0)); IntOGen NSD1 (driver in 15 cohorts (Act 3, LoF 12); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone methyltransferase that dimethylates Lys-36 of histone H3 (H3K36me2). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context. Location: Nucleus; Chromosome (UniProt). Locus 5q35.3 (HGNC).
- Leukaemia: Open Targets association 0.67 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.66 with myeloproliferative neoplasm (MONDO_0020076)
- Head and neck squamous cell carcinoma: Open Targets association 0.54 with head and neck squamous cell carcinoma (MONDO_0010150); IntOGen driver in 4 cohorts (HNSC)
- Endometrial cancer: IntOGen driver in 2 cohorts (UCEC)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Cervical cancer: IntOGen driver in 1 cohort (CEAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 12 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NSD1" OR ABSTRACT:"NSD1" OR TITLE:"nuclear receptor binding SET domain protein 1" OR ABSTRACT:"nuclear receptor binding SET domain protein 1" OR TITLE:"Histone-lysine N-methyltransferase, H3 lysine-36 specific" OR ABSTRACT:"Histone-lysine N-methyltransferase, H3 lysine-36 specific" OR TITLE:"ARA267" OR ABSTRACT:"ARA267" OR TITLE:"FLJ22263" OR ABSTRACT:"FLJ22263" OR TITLE:"KMT3B" OR ABSTRACT:"KMT3B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NSD1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTP63
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Cervical cancer, Bladder & urothelial cancer.
- TargetFBXW7
Shares Leukaemia (all types), Endometrial cancer, Oesophageal cancer, Non-Hodgkin lymphoma (all types).
- TargetCREBBP
Shares Leukaemia (all types), Oesophageal cancer, Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer.
- TargetSH2B3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, Non-Hodgkin lymphoma (all types).
- TargetCTCF
Shares Leukaemia (all types), Endometrial cancer, Non-Hodgkin lymphoma (all types), IntOGen.
- TargetNOTCH1
Shares Leukaemia (all types), Oesophageal cancer, Non-Hodgkin lymphoma (all types), Cervical cancer.
- TargetPRKCD
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen.
- TargetSTAG2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Endometrial cancer, Bladder & urothelial cancer.